Campo DMC, Hernández GJL, Gato SY, Valdés SC, Fortún PA

Language: Spanish
References: 14
Page: 146-154
PDF size: 159.96 Kb.

ABSTRACT

Introduction: although the existence of hemostasis disorders as part of type-III Ehlers-Danlos syndrome has not been confirmed, several coagulation alterations have been reported in isolated cases such as: deficiencies and modification in electrophoresis mobility of fibronectin, dysfunction of platelet aggregation with lengthening of bleeding time, deficiency of VIII, IX, XII and XIII factors and increase of aspirin sensitivity, among others.
Objective: evaluate the existence of hemostasis disorders in children with type III Ehlers-Danlos syndrome.
Method: an applied, observational, descriptive and cross-sectional research was carried out in 305 children suffering from type-III Ehlers_Danlos syndrome to evaluate in those having history of hemorrhagic manifestations, the existence of alterations of the hemostasis. Previous suspension of drugs with platelet anti-aggregation action, coagulation and platelet aggregation function studies were carried out.
Results: the study revealed that 181 patients presented history of spontaneous or traumatic bleeding mainly mucous-cutaneous. Coagulogram was normal in all cases and peripheral-blood smears showed the presence of macro-platelets and deficient formation of clots as the most frequent alteration. Aggregation and platelet function tests evidenced the presence of qualitative disorders, where a decrease of aggregation prevailed with the use of adenosine diphosphate (ADP), alone or combined with epinephrine and collagen, and with less frequency, disorders of of platelet phospholipids availability. The majority of these patients presented history of long-lasting use of antihistamines (ketotifen) due to diverse causes.
Conclusions: the occurrence of these qualitative platelet defects in children with EDS-type III is reported, standing out the role of the use of antihistamine drugs on the onset of the hemorrhagic symptoms in these patients.

REFERENCES

1. Ceccolini E, Schwartz R. Ehlers-Danlos Syndrome. 2006. [Citado 12 September 2007]. Disponible en: http://emedicine.medscape.com/article/1114004-overview

2. Beighton P, De Paepe A, Steimann B, Tsipouras P, Wenstrup RJ. Ehlers-Danlos syndrome: revisednosology, Villfranche, 1997. Ehlers-Danlos National Foundation (USA) and Ehlers-Danlos Support Group (UK). Am J Med Genet. 1998 Apr;77(1):31-7.

3. Levy H. Síndrome de Ehlers Danlos tipo hiperlaxitud. Revisión (SED tipo III, Síndorme de Ehlers-Danlos tipo III. Asociación Síndromes de Ehlers-Danlos e Hiperlaxitud 2001-2010 [actualizado 2011 Ene 25; citado 2011 Feb 20]. Disponible en: https://sites.google.com/site/rededargentina/sindrome-de-ehlers-danlos-tipohiperlaxitud.

4. De Paepe A, Malfait F. Bleeding and bruising in patients with Ehlers-Danlos syndrome and other collagen vascular disorders. Br J Haematol. 2004 Dec;127(5):491-500.

5. Hayward C. Clinical approach to the patient with bleeding or bruising. En: Hoffman: Hematology, basic principles and practice. 6th ed. Philadelphia: Churcill Livingstone Elsevier. 2013. p. 1847-56.

6. Onel D, Ulutin SB, Ulutin ON. Platelet defect in a case of Ehlers-Danlos syndrome. ActaHaematol 1973;50:238-44.

7. Beighton P, De Paepe A, Steimann B, Tsipouras P, Wenstrup RJ. Ehlers-Danlos syndrome: revised nosology. Villafrance, 1997. Ehlers-Danlos National Foundation (USA). Ehlers-Danlos Support Group (UK). Am J Med Genet 1998;77:31-37.

8. Toneguzzo J, Fourcans G, Gagliardo E, Rodríguez M, Cattaneo M, Izaquirre G, et al. Trastornos plaquetarios. Facultad de Ciencias Médicas. Universidad Nacional de Rosario; Argentina. 2009. [acceso: 4 de junio de 2013]. Disponible en: http://www.clinica-unr.com.ar/Downloads/Revisiones%20- %20Trastornos%20plaquetarios.pdf

9. Kashiwagi H, Riddle JM, Abraham JP, Frame B. Functional and ultrastructural abnormalities of platelets in Ehlers-Danlos syndrome. Ann Intern Med. 1965;63:249-54.

10. Yenicesu I, Ucan D, Soysal A, Büyükasik Y, Gümrük F. Platelet reliase defect in a child with Ehlers-Danlos syndrome. Pediatr Hematol Oncol. 2000;17:193-4.

11. Tofts LJ, Elliott EJ, Munns C, Pacey V, Sillence DO. The differential diagnosis of children with joint hypermobility: review of the literature. Pediatric Rheumatol. 2009;7:1-10.

12. Campo MC, Fortún Campo A, Beades A, Gato Y, Valdés C. Caracterización del síndrome de Ehlers-Danlos tipo III en Pinar del Río. Rev Ciencias Med (Pinar del Río). 2013 May-Jun:17(3);16-24.

13. Díaz M, Ricart G, Escobar A. Mecanismos moleculares de interacción de las plaquetas con el sub-endotrelio vascular: métodos de exploración. En: Hoffman´s Hematology: Basic Principles and Practice, 5th ed. Philadelphia: Churchill Livingstone Elsevier. 2009;1617-2017.

14. Sharathkumar AA, Shapiro AD. Trastornos de la función plaquetaria. Federación Internacional de Hemofilia. Québec. 2ª. ed. 2008.